Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin
Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin
This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Roche reported 2014 global sales of its Her2 antibody franchise consisting of Herceptin, Perjeta and Kadcyla, of US$ 8.3 bln, an increase of about 10% compared with sales of the previous year. The new Her2 antibodies not only should add sales, but importantly contribute to a change of the standard of care of breast cancer with conversion of Herceptin sales of PErjeta and Kadcyla sales as a major line of defence against the forthcoming biosimilar Herceptin launches starting in 2016/2017. However, in 2014 Herceptin sales were still growing with a 7 % increase compared with the previous year and make out about 81% of the franchise sale.
Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments, but also for biosuperior Her2 antibodies based on biparatopic and bispecific antibodies as well as Her2 antibodies with higher antitumor activities, e.g. by redirecting T cells, conferring cytotoxic paylods or radioisotopes.
The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of biosimilar and biosuperior Herceptin antibodies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Roche reported 2014 global sales of its Her2 antibody franchise consisting of Herceptin, Perjeta and Kadcyla, of US$ 8.3 bln, an increase of about 10% compared with sales of the previous year. The new Her2 antibodies not only should add sales, but importantly contribute to a change of the standard of care of breast cancer with conversion of Herceptin sales of PErjeta and Kadcyla sales as a major line of defence against the forthcoming biosimilar Herceptin launches starting in 2016/2017. However, in 2014 Herceptin sales were still growing with a 7 % increase compared with the previous year and make out about 81% of the franchise sale.
Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments, but also for biosuperior Her2 antibodies based on biparatopic and bispecific antibodies as well as Her2 antibodies with higher antitumor activities, e.g. by redirecting T cells, conferring cytotoxic paylods or radioisotopes.
The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of biosimilar and biosuperior Herceptin antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Marketed Her2 Antibodies:
Herceptin Sales & Pipeline
Perjeta Sales & Pipeline
Kadcyla Sales & Pipeline
Trastuzumab Biosuperiors:
Engineered Her2 Antibodies
Bi- and Multispecific Her2 Antibodies
Her2 Antibody-Drug Conjugates
Other Her2 Antibodies
Herceptin Biosimilars
Corporate Her2 Antibody Biosimilar & Biosuperior Pipelines
Herceptin Sales & Pipeline
Perjeta Sales & Pipeline
Kadcyla Sales & Pipeline
Trastuzumab Biosuperiors:
Engineered Her2 Antibodies
Bi- and Multispecific Her2 Antibodies
Her2 Antibody-Drug Conjugates
Other Her2 Antibodies
Herceptin Biosimilars
Corporate Her2 Antibody Biosimilar & Biosuperior Pipelines
